Recherche scientifique

Article paru "Infection et Immunité"

Infection and Immunity, June 1985, p.625 - 628
Copyright © 1985 American Society for Microbiology
Protection Against Escherichia coli-Induced Urinary Tract Infections with Hybridoma Antibodies Directed Against Type 1 Fimbriae or Complementary D-Mannose Receptors

SOMAN N. ABRAHAM,* JEGDISH P. BABU, CHRIS S. GIAMPAPA, DAVID L. HASTY, W. ANDREW SIMPSON, AND EDWIN H. BEACHEY
Veterans Administration Medical Center, Memphis, Tennessee 38104, and the University of Tennessee Center for the Health Sciences, Memphis, Tennessee 38163

Received 26 December 1984/Accepted 1 March 1985
Hybridoma antibodies directed against quaternary structural epitopes of the type 1 fimbrial adhesin of Escherichia coli or against D-mannose, the sugar determinant in the complementary host cell receptor, prevented the attachment of mannose-sensitive E. coli to various eucaryotic cells. Passive intraperitoneal administration of the fimbria-specific or D-mannose-specific antibodies protected mice against retrograde colonization with mannose-sensitive E. coli instilled into their urinary bladders. Monoclonal antibodies directed against fimbrial subunits rather than quaternary structural epitopes or against N-acetylgalactosamine rather than D-mannose residues lacked protective activity. These studies provide evidence that bacterial colonization can be blocked or interrupted by antibodies directed against either the adhesin or the complementary host cell receptor of pathogenic microorganisms.

Etude du Dr Michael Blue

D-MANNOSE & URINARY TRACT INFECTIONS (Including SCI)

Abstracted and Edited from a Report Submitted to Progressive Laboratories by Michael Blue, M.D., Urologist (Norman, OK)

See D-Mannose & UTI overview article

[Note from John and Anna - They didn't really know much about dose levels in this study. As we've repeatedly found to be true, both the curative and preventative effects of Waterfall D-Mannose can be greatly improved if dose levels are adjusted according to the severity of the symptoms, length of infection, and personal cystitis triggers. The amount of liquid intake is also important, as is avoiding acidifying the urine.]

INTRODUCTION:
D-Mannose is a natural occurring simple sugar that appears to be a safe, practical alternative for the treatment of urinary tract infections (UTI's). D-Mannose is absorbed eight times slower than glucose, and when ingested, is not converted to glycogen or stored in the liver, but rather goes directly to the blood stream from the upper GI tract. Hence, D-Mannose is mostly filtered through the kidneys and routed to the bladder. The bladder lining is comprised of polysaccharide molecules. Finger-like projections on the cell surface of E. coli b acteria adhere to these molecules, initiating an infection. In the presence of D-Mannose, E. coli preferentially attach to D-Mannose molecules forming a complex which is expelled with the next voiding. D-Mannose probably works 80-90% of the time because the bacteria disabled by Mannose causes 80-90% of UTI's. Whereas antibiotic treatment radically changes GI bacterial populations required for good health, potentially causing fungal or gastrointestinal infections, D-Mannose removes 'bad' bacteria by attachment and voiding. SUBJECTS:
Study subjects were Dr. Michael Blue's long-term patients, who had a history of reoccurring UTI's. Subjects included 42 females (12-83 years old) and 18 males (25-71 years old). After urine culture to determine specific bacterial cause, if any, subjects were started on a D-Mannose daily regimen.
RESULTS:
Of the 42 female subjects, 24 were confirmed by culture to have a UTI. In 19 cases (~80%), E. coli was the diagnosed cause, in four, Klebsiella, and in one, mixed bacteria.
In the confirmed culture group, two scoops of D-Mannose daily were given for one week. Of the 12 (50%) who returned for follow-up cultures, eight were negative. Patients indicated that the symptoms had disappeared.
Statistically, 17 of the 24 (71%) females in the confirmed-culture, D-mannose-treated group reported symptom improvement. Although three of the 24 (12.5%) were unable to be contacted, they did not return for additional treatment. Only four of 24 (17%) reported no symptom improvement after D-Mannose treatment.
Those females who were not confirmed by culture to have bacterial UTI but had UTI-associated symptoms were classified into a painful-bladder-syndrome (PBS) group. Of the 18 PBS females who were treated daily with two scoops of D-Mannose, 17 (94%) reported symptom improvement, the lone exception being a subject unable to be contacted, but also not returning for treatment. Eighty percent became totally symptom free.
Of the 18 male subjects, 10 were confirmed by culture to have a UTI. Seven had neurogenic bladders from spinal cord injuries, three of whom were on intermittent catheterization and four had indwelling supra-pubic tubes.
Two men had been incapacitated with recurrent sepsis, retention, and obstructive uropathy. Both men underwent insertion of supra pubic tubes. Once released from the hospital, both were placed on a D-Mannose daily regimen. Improvement was suggested by their ability to avoid additional hospitalization.
In the group diagnosed with E. coli-related UTI and treated with D-Mannose, significant improvement was reported. Due to the composition of the male group, few responded as dramatically as females.
FINDINGS:
Consistent with existing literature, about 50% of those reporting UTI symptoms were actually confirmed by culture to possess bacterial infection. The therapeutic use of D-Mannose on acute UTI's in this study was effective in eliminating or ameliorating symptoms.
In addition, 80% of the painful-bladder-syndrome group became symptom free using D-Mannose.
Over the six-month study, three females with different issues showed especially noteworthy responses to D-Mannose. The first was a 50-year old female with neurogenic bladder and incontinence suffering from a monthly UTI. Endoscopically, her bladder revealed numerous areas compatible with recurrent UTI's. After three months of D-Mannose, her urine was sterile, and her bladder mucosa returned to normal. The second woman complained about bladder pain for which she had received numerous, unsuccessful therapies. After one week of D-Mannose, her pain ceased. The third woman presented an E. coli infection and pronounced structural findings in her bladder called Cystitis Cystica, all of which disappeared after three months on D-Mannose. In conclusion, D-Mannose appears to effectively treat simple, uncomplicated UTI's.